BIOMAT Database Logo BIOMAT Database Logo

[Eye changes in hyperlipoproteinaemia type IV and V (author's transl)]. 1977

K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005123 Eye The organ of sight constituting a pair of globular organs made up of a three-layered roughly spherical structure specialized for receiving and responding to light. Eyes
D005128 Eye Diseases Diseases affecting the eye. Eye Disorders,Eye Disease,Eye Disorder
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses

Related Publications

K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
[Xantinol-nicotinate in primary type-V hyperlipoproteinaemia (author's transl)].
September 1976, Deutsche medizinische Wochenschrift (1946),
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
[The lipid reducing action of phenformin in primary type IV hyperlipoproteinaemia (author's transl)].
November 1973, Deutsche medizinische Wochenschrift (1946),
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
[Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
August 1977, Klinische Wochenschrift,
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
Type-IV hyperlipoproteinaemia.
October 1968, Lancet (London, England),
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
Type IV hyperlipoproteinaemia.
March 1973, Clinics in endocrinology and metabolism,
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
Type V hyperlipoproteinaemia.
March 1973, Clinics in endocrinology and metabolism,
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
[Type II hyperlipoproteinaemia treated with etiroxate (author's transl)].
October 1979, Casopis lekaru ceskych,
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
[Generalized ceroid histiocytosis in type 5 hyperlipoproteinaemia (author's transl)].
November 1979, Wiener klinische Wochenschrift,
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
A clinical syndrome characteristic of primary Type IV-V hyperlipoproteinaemia.
March 1974, The British journal of dermatology,
K Majewska, and K Czechowicz-Janicka, and M Ciswicka-Sznajdermanowa
[Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
March 1976, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!